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ABSTRACT
Aim Autoimmune thyroid disease (AITD) is a multifactorial dise-
ase with a genetic predisposition. The protein tyrosine phosphata-
se-22 (PTPN-22) gene is a powerful inhibitor of T-cell activation. 
The aim of this study was to compare messenger RNA (mRNA) 
PTPN22 expression between healthy persons and patients with 
hypothyroidism and with their affected relatives. 
Methods This was a cross-sectional, prospective and descriptive 
study. DNA was extracted from leukocytes (4,000-10,000 cells) 
using the Magna Pure LC 2.0 Instrument and MagNA Pure LC 
RNA Isolation Kit I (Roche, Germany). A real-time polymerase 
reaction (qPCR) was performed utilizing the primer sets specific 
for the PTPN-22 gene, and the succinate dehydrogenase complex, 
the subunit A, Flavoprotein (Fp) (SDHA) constitutive gene. All re-
actions were performed with the 7500 Fast Real Time PCR System 
(Applied Biosystems, Applera International, Inc. Cheshire, UK) 
employing the SYBR Advantage qPCR Premix Kit (Clontech, 
USA). 
Results Twenty five patients with AITD (hypothyroidism), all fe-
males (mean age 39.6 ± 11.8 years) and 23 control subjects (mean 
age 24.4 ± 4.2 years) were included in the study. There was no 
statistical difference between both groups in PTPN-22 mRNA 
expression (p = 0.125). 
Conclusion There is no clear difference in mRNA PTPN-22 
expression. The ideal genes for a systematic screening for familial 
AITD are yet to be found. 
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INTRODUCTION
Autoimmune thyroid disease (AITD) is the 
most common autoimmune condition, affecting 
approximately 2% of the female population and 
0.2% of the male population (1). Although the 
exact etiology is not yet known, AITD is multi-
factorial in that a genetic predisposition combi-
nes with environmental risk factors to promote 
disease (2,3). 
Up to 90% of patients with AITD-related 
hypothyroidism are anti-thyroid peroxidase 
(TPO) antibody-positive. It should be noted that 
10–15% of the general population are positive 
for anti-TPO antibodies and that low titers are 
less specific for AITD (2). 
Symptoms of hypothyroidism may be subtle, 
even with marked biochemical derangement, but 
as the disease progresses, subclinical and then 
clinical hypothyroidism appears. In the early sta-
ges of hypothyroidism, the thyroid stimulating 
hormone (TSH) may be normal and anti-thyrope-
roxidase (TPO) antibodies may be positive with 
or without goiter. Later, TSH elevation becomes 
modest (5–10 IU/ml) with a normal FT4 (bioche-
mical or subclinical hypothyroidism). 
Some studies have reported that siblings of per-
sons affected by Graves disease or hypothyro-
idism have a 33% chance of developing the 
disease (4). In the casuistry of Ciprés Grupo 
Médico (CGM), Toluca, Mexico, the percentage 
of mothers with AITD and with an affected dau-
ghter is 13% (5).
The first gene found to be associated with both 
Graves disease and hypothyroidism was HLA-
DR3. Since this discovery, significant progress 
has been made in the genetic contributions and 
the mechanisms underlying thyroid autoimmu-
nity. To date, several loci have been associated 
with AITD. In addition to HLA-DR subtypes, the-
se include two groups of the non-major histocom-
patibility complex (MHC) genes, e. g., immu-
noregulatory genes (CD40, CTLA-4, PTPN-22, 
FOXP3, and CD25), and thyroid-specific genes 
(Tg and TSHR) (6,7). Polymorphic variations of 
all these genes have been identified and linked 
with AITD susceptibility, but the existing studies 
have often given inconsistent results, with some 
showing associations and others not (8,9). One 
of the many unexpected findings of these gene-
tic studies is that the majority of the genes iden-
tified exert very minor effects (10). Indeed, with 
the exception of the DRb1-Arg74 HLA variant, 
which resulted in an Odds ratio (OR) for Graves’ 
disease of >5, all of the remaining AITD genes 
gave very low OR of <1.5 (11); on the other hand, 
family history is positive in about 50% of patients 
with AITD. It is usually supposed that a strong 
genetic effect in the disease is related with the in-
heritance of many genes with small effect (12).
Lymphoid tyrosine phosphatase (Lyp) encoded 
by protein tyrosine phosphatase-22 (PTPN-22) 
gene locus on chromosome 1p13.3–13.1, such 
as CTLA-4, is a powerful inhibitor of T-cell ac-
tivation (13). A single nucleotide polymorphism 
in PTPN-22 has been reported as an autoimmune 
susceptibility locus that associates with type 1 
diabetes (14), rheumatoid arthritis (15), systemic 
lupus erythematosus (16), Hashimoto’s thyroi-
ditis (17), Graves’ disease (18), Addison’s dise-
ase (19), Myasthenia gravis (20), vitiligo (21), 
systemic sclerosis (22), and juvenile idiopathic 
arthritis (23), suggesting that allelic variants of 
PTPN-22 could predispose to a more general au-
toimmune diathesis.
Protein tyrosine phosphatase and protein tyro-
sine kinases (PTKs) are enzymes that specifi-
cally catalyze the reversible addition or release 
of phosphate groups from tyrosine residues on 
signaling intermediates. Broadly speaking, PTK 
amplify signals, while the mode, tempo and du-
ration of the signal are governed by PTP. Protein 
tyrosine phosphatase and PTK are divided into 
two groups: receptor (membrane bound-RPTP or 
RPTK) or non-receptor (cytoplasmic-NRPTP or 
NRPTK) (24). 
Aim of this study was to compare mRNA PTPN-




This was a cross-sectional prospective and des-
criptive study conducted at the Medical Sciences 
Research Center (CICMED), Autonomous Uni-
versity of the State of Mexico (UAEMex) and at 
the Ciprés Grupo Médico (CGM), both in Toluca, 
Mexico, from August 2013 to July 2014. Dia-
gnosis of thyroidopathy was made based on the 
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presence of a thyroid profile with TSH ≥ 10 IU 
together with a significant titer of autoantibodies 
(anti-thyroglobulin > 40 IU or anti-TPO > 35 IU).
The study was approved by the Institutional Re-
view Board of the Medical Sciences Research 
Center (CICMED), UAEMex (25/09/13) and 
was performed according to the ethical standards 
of the Helsinki Declaration (Fortaleza, Brazil). 
Written informed consents were obtained from 
all patients and their relatives who participated 
in this project. 
Sample calculation
Accepting an alpha risk of 0.05 and a beta risk of 
0.2 in a two-sided test, 25 subjects per group were 
required for the recognition as statistically signi-
ficant of a difference  ± 4 relative units (RU). The 
common standard deviation was assumed to be 5. 
Clinical measurements
Weight (kg), height (m) (Seca, GmbH, Germany) 
and waist circumference (cm) were measured in all 
participants. Body mass index (BMI) was calcula-
ted as weight (kg) divided by height (m) squared. 
RNA extraction
A blood sample (vacutainer tubes) was taken 
from each patient. Leukocytes were obtained 
according to the ACK-lysing buffer (LONZA) 
protocol. Briefly, a peripheral blood sample was 
placed in an EDTA tube and then centrifuged at 
2,500 rpm for 10 min. All samples were maintai-
ned at -80°C until further analysis.
The RNA was extracted from leukocytes (4,000-
10,000 cells) in the Magna Pure LC 2.0 Instrument 
using the MagNA Pure LC RNA Isolation Kit I 
(Roche, Germany). After extraction, the RNA 
was quantified using a Nano Photometer (Implen 
GmbH, Germany), reporting concentration (in μg/
mL) and purity (as 260/280 absorbance).
Gene expression
A total of 200–400 ng total mRNA was reverse-
transcribed into complementary RNA (cDNA) 
utilizing a Transcriptor High Fidelity cDNA 
Synthesis Kit (Roche Applied Science). The 
amount of extracted RNA was quantified by me-
asuring the absorbance at 260 nm. The purity of 
the RNA was assessed according to the ratio of 
the absorbance values at 260 and 280 nm; purity 
ranged between 1.8 and 2.1, demonstrating a 
high RNA quality. The samples were measured 
with a NanoPhotometer (Implen GmbH, Ger-
many), and the extracts were then adjusted to 
a concentration of 20 μg RNA L−1 for the PCR 
reaction. A real-time Polymerase chain reaction 
(qPCR) was performed using the primer sets 
specific for the PTPN-22 (NM_001193431.1) 
as follows: forward: 5’-AGGCAGA-
CAAAACCTATCCTACA-3’, reverse: 
5’-TGGGTGGCAATATAAGCCTTG-3’ and 
the succinate dehydrogenase complex, subu-
nit A, flavoprotein (Fp) (SDHA) constituti-
ve gene (NM_004168) as follows:, forward: 
5’-AGAGGGAGGCATTCTCATTAAC-3’, re-
verse: 5’-ACCGAGACACCACATCTCTA-3’. 
All reactions were performed with the 7500 Fast 
Real Time PCR System (Applied Biosystems, 
Applera International, Inc., Cheshire, UK) 
using the SYBR Advantage qPCR Premix Kit 
(Clontech). The expression levels of the genes 
were examined by placing 4 μL of the reverse 
transcription mix for each PCR reaction in a to-
tal volume of 20 μL. The thermal cycling condi-
tions were as follows: 10 min at 95°C followed 
by 45 cycles of denaturation at 95°C for 15 sec 
and annealing/extension at 60°C for 1 min. The 
comparative threshold cycle (CT) method was 
used to calculate fold amplification, as specified 
by the manufacturer.
The Taguchi method was employed to set the 
best conditions for primer amplification. The fold 
change in PTPN-22 was normalized against the 
constitutively expressed reference gene and then 
compared with the controls (healthy volunteers) 
as follows: 2−ΔΔCT, where ΔΔCT=(CT-target − 
CT-reference) treated-sample − (CT-target − CT-
reference) calibrator-sample. Calibrator-sample 
refers to the expression level (1×) of the target 
gene normalized to the constitutive gene. The ca-
librator was chosen from healthy volunteers and 
was given a relative expression value of 1.
Statistical analysis
Statistical analysis was performed using the 
Mann–Whitney U-test after performing the Le-
vene test. The normality hypothesis was tested 
using the Kolmogorov-–Smirnov test. Statistical 
significance was tested at the p ≤0.05 level.
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RESULTS
Twenty five patients with AITD (hypothyroidi-
sm), all females (mean age, 39.6 ± 11.8 years) and 
23 control subjects (mean age, 24.4 ± 4.2 years) 
were included in the study. In Table 1, we depict 
the affected relatives of the patients, which inclu-
ded one case for a grandmother, nine cases for a 
mother, one for a father, seven for a sister, one for 
a brother, four for an aunt, one for an uncle, and 
six for a cousin. Average time of disease evoluti-
on was 18.4 ± 24.2 months prior to participation 
in this study with a mean Levothyroxine dose of 
66.2 ± 23.3 μg per day. 
ents with affected relatives, the 50th percentile of 
PTPN-22 expression was 1.13 RU (Figure 1).


























Table 1. Characteristics of thirty three affected relatives in 25 
patients with autoimmune hypothyroidism
*maternal, †paternal
Figure 1.
Anthropometrically, while the patients showed a 
BMI of 24.7 ± 2.4, the control group showed one 
of 25.1 ± 1.7. 
According to the place of residence there were 
12 patients from Toluca, five from Mexico City, 
four from Metepec, and one patient from each 
Otzolotepec, Naucalpan, Zinacantepec, and Gua-
dalajara.
In relation to antibodies, six patients were positi-
ve for anti-thyroglobulin, five for anti-TPO, and 
14 for both. 
In the qPCR analysis there was no statistically si-
gnificant difference in PTPN-22 expression betwe-
en both groups (p=0.125). In the subgroup of pati-
DISCUSSION
The comparable prevalence and incidence of 
AITD in geographically different populations 
suggest a significant genetic effect (19,20). In 
this regard, the purpose of this study was not to 
associate a geographical location with AITD, due 
to lack of information related with this topic in 
Latin America. In another line, obesity has been 
postulated as a factor linked to the cause of AITD 
(21). Although this is a strong argument, in our 
sample population this possible link does not 
play a critical role as the patients maintained a 
normal BMI.
In all patients with associated diseases, AITD is 
usually detected in its initial phase when thyroid 
function is preserved, with normal or only sli-
ghtly elevated TSH levels. At this stage, signs 
and symptoms of thyroid disease are usually 
absent, but because worsening of thyroid func-
tion is a possibility, early recognition of thyroid 
dysfunction is necessary to prevent the negative 
effects of hypothyroidism on growth and meta-
bolic function (16). In our study, we evaluated 
patients who had been already diagnosed.
Subclinical thyroid disease is a common clinical 
problem, and because the majority of patients are 
asymptomatic, screening is the only way to de-
tect the condition in most patients (22). 
In our study, we performed an initial familial sur-
vey without finding a clear difference in PTPN-
22 mRNA expression. This is in accordance with 
Inoue et al. whose authors only found an associa-
tion of CD40 and FCRL3 gene polymorphisms 
with Graves’ disease intractability, and a ZFAT 
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polymorphism association with Hashimoto’s di-
sease severity, but neither PTPN-22 -1123C/G 
nor PTPN22 SNP37 were associated with any 
option (23). Contrariwise, Ichimura et al. found 
an association of the SNP37 of the PTPN-22 
gene with susceptibility to Graves’ disease in a 
Japanese population (24). 
In an initial attempt, a difference in PTPN-22 
expression between familiar hypothyroidism and 
healthy subjects cannot be concluded from our 
results. In contrast, several other genes have been 
tested without a definitive conclusion (25-26) but 
of these genes taken together probably do not 
explain more than about 10% of the heritability 
of AITD (27). 
We cannot exclude two kinds of bias in our stu-
dy: recall bias and ‘lead-time’ bias. In the first 
case, we registered four patients with affected 
relatives who initially denied knowing another 
relative suffering from hypothyroidism until a 
second clinical interview. In the second type of 
bias, it is possible that, with a different evolution 
time with biochemical hypothyroidism, PTPN-
22 expression could exhibit different patterns. 
Unfortunately, our sample size limits us to per-
form a stratified analysis. Expecting a lower RU 
difference between healthy subjects and families 
affected with AITD implies a higher number of 
persons per group to be analyzed.
The question pertaining to how to explain the fa-
milial heritability may be more straightforward. 
First, the female preponderance is explained 
partially by fetal microchimerism and X-chro-
mosome inactivation (27). Second, imprinted ge-
nes and epistasis, the modification of expression 
of one gene by one or several other genes, are 
believed to be important genetic contributors to 
complex diseases. We could not forget that in 
addition to the gene–gene interactions, the clini-
cal phenotype of affected individuals is also in-
fluenced by gene–environment interactions (28).
In summary, the results of our study indicate that 
the ideal genes for systematic AITD screening 
continue to be missing, but these must be defined 
in order to be carried out in relatives of patients 
with AITD, including the offspring of these pa-
tients. PTPN-22 remains a possible gene candi-
date for further study including its promiscuous 
association with familial AITD, but it would be 
better to study a set of genes. Such a determina-
tion would have huge implications in our current 
screening strategies for diagnosing earlier novel 
thyroidopathies.
Admittedly, the sample size of our family collecti-
on remained insufficiently large for conclusion of 
and exclusion of the participation of PTPN-22 in 
the genesis of AITDs in Mexican population, but 
we must take into account that studies in different 
geographic regions revealed ethnic differences in 
associations most probably due to founder effects 
and/or to the presence or absence of certain vari-
ants in specific ethnic groups (4-8). Further studies 
including proteomic analyses are required.
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